Quantcast
Last updated on April 18, 2014 at 12:48 EDT

Latest Argen Stories

2014-01-13 04:21:01

BREDA, The Netherlands and GHENT, Belgium, January 13, 2014 /PRNewswire/ -- Enters into pilot research agreement with Boehringer Ingelheim arGEN-X, a clinical stage human therapeutic antibody company, announces the attainment of two important success milestones in its SIMPLE Antibody(TM) research and product development collaboration with Shire. The milestones, which trigger undisclosed payments from Shire, relate to demonstration of in vivo proof of concept...

2013-11-04 04:21:59

BREDA, The Netherlands and GHENT, Belgium, November 4, 2013 /PRNewswire/ -- Funds to advance ARGX-113, a novel antibody fragment approach to promote degradation and clearance of disease-causing autoantibodies, towards clinical development arGEN-X, a clinical stage human therapeutic antibody company, has raised EUR 5 million ($6.8 million) as an extension of its series B financing round from the Flemish investment company PMV as a new investor. arGEN-X' series B round,...

2012-10-25 03:21:27

BREDA, the Netherlands and GHENT, Belgium, October 25, 2012 /PRNewswire/ -- arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody(TM) platform, has strengthened its supervisory board with the appointment of Dr. David L. Lacey. Dr. Lacey is a former Senior Vice President and Head of Discovery Research at Amgen with over 30 years of basic and clinical research experience. He played a...

2012-10-04 02:26:24

LA JOLLA, Calif., BREDA, Netherlands and GHENT, Belgium, Oct. 4, 2012 /PRNewswire/ -- RuiYi (formerly Anaphore) and arGEN-X BV announced today that arGEN-X has granted a worldwide exclusive license to RuiYi to develop and commercialize ARGX-109, a novel anti-IL-6 monoclonal antibody discovered and developed by arGEN-X. Under the agreement, RuiYi will make an upfront payment to arGEN-X consisting of cash and equity. arGEN-X is also eligible to receive additional payments based on the...